Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)

(2014) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

The concept of spondyloarthritis: Where are we now?

(2014) Neha Garg et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Axial spondyloarthritis criteria and modified NY criteria: issues and controversies

(2014) Atul Deodhar   CLINICAL RHEUMATOLOGY

Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy

(2013) Mohammed Hammoudeh et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

(2013) Dominique Baeten et al.   LANCET

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis

(2012) Ejaz Pathan et al.   ANNALS OF THE RHEUMATIC DISEASES

Fatigue in Ankylosing Spondylitis: Treatment Should Focus on Pain Management

(2012) Sinead Brophy et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

(2011) J. Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis

(2011) Troy Noordenbos et al.   ARTHRITIS AND RHEUMATISM

New treatment targets in ankylosing spondylitis and other spondyloarthritides

(2011) In-Ho Song et al.   CURRENT OPINION IN RHEUMATOLOGY

Current therapeutics for spondyloarthritis

(2011) Éric Toussirot   EXPERT OPINION ON PHARMACOTHERAPY

Psychometric characteristics of the short form 36 health survey and functional assessment of chronic illness Therapy-Fatigue subscale for patients with ankylosing spondylitis

(2011) Dennis A Revicki et al.   Health and Quality of Life Outcomes

Th17 Cells Expressing KIR3DL2+ and Responsive to HLA-B27 Homodimers Are Increased in Ankylosing Spondylitis

(2011) P. Bowness et al.   JOURNAL OF IMMUNOLOGY

Fatigue in patients with ankylosing spondylitis: prevalence and relationships with disease-specific variables, psychological status, and sleep disturbance

(2011) N. Aissaoui et al.   RHEUMATOLOGY INTERNATIONAL

Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Sp

(2011) Jane Zochling   ARTHRITIS CARE & RESEARCH

Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry

(2010) B. Glintborg et al.   ANNALS OF THE RHEUMATIC DISEASES

Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis

(2010) Yang Mei et al.   CLINICAL RHEUMATOLOGY

Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: Results from a randomized, placebo-controlled trial

(2010) Atul Deodhar et al.   ARTHRITIS CARE & RESEARCH

The comparative one-year performance of anti–tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study

(2008) Marte Schrumpf Heiberg et al.   ARTHRITIS AND RHEUMATISM